Mark Jeffrey DeLong - 28 Jan 2026 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Business & Strat Officer
Signature
/s/ David Watson, attorney-in-fact for Mark DeLong
Issuer symbol
APLS
Transactions as of
28 Jan 2026
Net transactions value
$0
Form type
4
Filing time
30 Jan 2026, 16:11:45 UTC
Previous filing
23 Jan 2026
Next filing
13 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DeLong Mark Jeffrey Chief Business & Strat Officer C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM /s/ David Watson, attorney-in-fact for Mark DeLong 30 Jan 2026 0001856078

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +36,606 +47% $0.000000 114,959 28 Jan 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service.